Dupixent® FDA approval call



Sanofi and Regeneron hosted a conference call & webcast following the approval of Dupixent® for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), a serious, chronic inflammatory skin disease.

The presentation was followed by a Q&A session.